Nicholas W Carris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1870898/publications.pdf

Version: 2024-02-01

1162367 996533 29 240 8 15 citations g-index h-index papers 29 29 29 360 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Semaglutide for Weight Loss. Annals of Pharmacotherapy, 2022, 56, 224-226.	0.9	2
2	Cardiovascular and microvascular outcomes with <scp>iGlarLixi</scp> versus <scp>iDegLira</scp> : A realâ€world, populationâ€based cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 348-353.	2.2	2
3	Practicable Measurement and Identification of Overbasalization. Clinical Diabetes, 2022, 40, 75-77.	1.2	2
4	Novel biomarkers of inflammation in heart failure with preserved ejection fraction: analysis from a large prospective cohort study. BMC Cardiovascular Disorders, 2022, 22, 221.	0.7	3
5	Ambulatory Care Pharmacists' Perception of Prediabetes. Journal of Pharmacy Practice, 2021, 34, 70-77.	0.5	1
6	Review of Prediabetes and Hypertensive Disorders of Pregnancy. American Journal of Perinatology, 2021, 38, 428-435.	0.6	1
7	Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?. Drugs, 2021, 81, 881-893.	4.9	9
8	Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. JAMA - Journal of the American Medical Association, 2021, 326, 1329.	3.8	3
9	Prediabetes: An Undiagnosed Pandemic. Endocrine Practice, 2021, , .	1.1	1
10	Open data, trials and new ethics of using others' work. Journal of Medical Ethics, 2021, 47, e34-e34.	1.0	1
11	Impact of Metformin on Statin Persistence: a Post Hoc Analysis of a Large Randomized Controlled Trial. Journal of General Internal Medicine, 2020, , 1.	1.3	O
12	Searching for the lowest effective opioid dose: A framework for acute pain from the National Academies. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 1158-1160.	0.5	0
13	Prevention of Diabetes Mellitus in Patients With Prediabetes. American Journal of Cardiology, 2019, 123, 507-512.	0.7	31
14	Metformin's impact on statinâ€associated muscle symptoms: An analysis of ACCORD study data and research materials from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center. Diabetes, Obesity and Metabolism, 2018, 20, 1994-1999.	2.2	5
15	Evaluation of SAMe-TT2R2 Score on Predicting Success With Extended-Interval Warfarin Monitoring. Annals of Pharmacotherapy, 2018, 52, 1085-1090.	0.9	O
16	The changing cost to prevent diabetes: A retrospective analysis of the Diabetes Prevention Program. Journal of the American Pharmacists Association: JAPhA, 2017, 57, 717-722.	0.7	8
17	Pleiotropic effects of metformin to rescue statin-induced muscle injury and insulin resistance: A proposed mechanism and potential clinical implications. Medical Hypotheses, 2017, 107, 39-44.	0.8	10
18	Patient satisfaction with extended-interval warfarin monitoring. Journal of Thrombosis and Thrombolysis, 2016, 42, 486-493.	1.0	8

#	Article	IF	CITATIONS
19	EPA-Registered Repellents for Mosquitoes Transmitting Emerging Viral Disease. Pharmacotherapy, 2016, 36, 1272-1280.	1.2	21
20	Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. Journal of the American Society of Hypertension, 2016, 10, 307-317.	2.3	28
21	First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women. Annals of Pharmacotherapy, 2016, 50, 125-132.	0.9	9
22	Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. Journal of Human Hypertension, 2016, 30, 191-196.	1.0	16
23	Minocycline as A Substitute for Doxycycline in Targeted Scenarios: A Systematic Review. Open Forum Infectious Diseases, 2015, 2, ofv178.	0.4	30
24	Management Strategies for Clopidogrel Hypersensitivity. Drugs, 2015, 75, 999-1007.	4.9	5
25	Quality of Life in Treatment-Resistant Hypertension. Current Hypertension Reports, 2015, 17, 61.	1.5	12
26	Feasibility of Extended-interval Follow-up for Patients Receiving Warfarin. Cardiovascular Therapeutics, 2015, 33, 98-103.	1,1	9
27	New Pharmacological Therapies for Vasomotor Symptom Management. Annals of Pharmacotherapy, 2014, 48, 1343-1349.	0.9	5
28	Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations. Drugs, 2014, 74, 2141-2152.	4.9	18
29	Impact of Overbasalization on Clinical Outcomes in Patients With Type 2 Diabetes: A Post-Hoc Analysis of a Large Randomized Controlled Trial. Clinical Diabetes, 0, , .	1.2	O